RBC quarterly biotechnology update

RBC is recommending that investors stay with companies driven by top and bottom line earnings growth and robust pipelines, even though large caps are underperforming (down 10%).

Upcoming product approvals adding to a robust flow of news include Cubicin for endocarditis/bacteremia, Tysabri for multiple sclerosis, Lucentis for wet AMD and Avastin for lung cancer.

RBC picks Gilead Sciences for best large cap for its HIV franchise, management and outperforming revenue and earnings.

Cubist Pharmaceuticals is RBC's favored small cap pick for its first-in-class antibiotic and its emerging profitability.

RBC upgraded Adolor to outperform from perform based on phase 3 data for Entereg. Biogen moved up to outperform from perform on the positive Tysabri panel review and the drug's billion-dollar potential.

The Medicines Co. was downgraded to underperform from perform on lack of forecast sales and lack of a label in the Acuity data, coupled with a potentially slow cath lab market.

RBC is adding inhaled drug developer Alexza Pharmaceuticals to its coverage with an outperform, above average risk rating.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.